Answers are grounded in this paper and cite their sources.
// Jia Zhou 1, * , Yixuan Zhao 1, * , Vera Simonenko 2, * , John J. Xu 3 , Kai Liu 1 , Deling Wang 3 , Jingli Shi 3 , Tianyi Zhong 3 , Lixia Zhang 3 , Lun Zeng 4 , Bin Huang 4 , Shenggao Tang 5 , Alan Y. Lu 5 , A. James Mixson 6 , Yangbai Sun 1 , Patrick Y. Lu 2 and Qingfeng Li 1 1 Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 2 Sirnaomics, Inc., Gaithersburg, MD, USA 3 Suzhou Sirnaomics Pharmaceuticals, Ltd., Biobay, Suzhou, China 4 Guangzhou Xiangxue Pharmaceuticals, Co. Ltd., Guangzhou, China 5 Guangzhou Nanotides Pharmaceuticals, Co. Ltd., Guangzhou, China 6 Department of Pathology, School of Medicine, University of Maryland, Baltimore, MD, USA * These authors contributed equally to this work and share co-first authorship Correspondence to: Qingfeng Li, email: dr.liqingfeng@shsmu.edu.cn Patrick Y. Lu, email: plu@sirnaomics.com Yangbai Sun, email: drsunyb@foxmail.com Keywords: siRNA therapeutics, hypertrophic scar, TGF-β1, COX-2, synergistic effect Received: November 16, 2016 Accepted: August 26, 2017 Published: September 14, 2017 ABSTRACT Excessive skin scars due to elective operations or trauma represent a challenging clinical problem. Pathophysiology of hypertrophic scars entails a prolonged inflammatory and proliferative phase of wound healing. Over expression of TGF-β1 and COX-2 play key regulatory roles of the aberrant fibrogenic responses and proinflammatory mediators. When we silenced TGF-β1 and COX-2 expression simultaneously in primary human fibroblasts, a marked increase in the apoptotic cell population occurred in contrast to those only treated with either TGF-β1 or COX-2 siRNA alone. Furthermore, using human hypertrophic scar and skin graft implant models in mice, we observed significant size reductions of the implanted tissues following intra-scar administration of TGF-β1/COX-2 specific siRNA combination packaged with Histidine Lysine Polymer (HKP). Gene expression analyses of those treated tissues revealed silencing of the target gene along with down regulations of pro-fibrotic factors such as α-SMA, hydroxyproline acid, Collagen 1 and Collagen 3. Using TUNEL assay detection, we found that the human fibroblasts in the implanted tissues treated with the TGF-β1/COX-2 siRNAs combination exhibited significant apoptotic activity. Therefore we conclude that a synergistic effect of the TGF-β1/COX-2siRNAs combination contributed to the size reductions of the hypertrophic scar implants, through activation of fibroblast apoptosis and re-balancing between scar tissue deposition and degradation.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: